150
Participants
Start Date
April 30, 1997
Primary Completion Date
December 31, 2029
Study Completion Date
December 31, 2029
Acetazolamide
250 mg PO x 1
Atomoxetine
10-40 mg PO x 1 dose
NO Drug
No intervention - just monitoring
Clonidine
Clonidine 0.05-0.3 mg PO x 1 dose
Entacapone
Entacapone 200-400 mg PO x 1 dose
Entacapone & Propranolol
Entacapone 200-400 mg PO x 1 dose AND propranolol 20 mg PO x 1 dose
Atomoxetine & Propranolol
Atomoxetine 10-40 mg PO x 1 dose AND propranolol 20 mg PO x 1 dose
Indomethacin
Indomethacin 25-50 mg PO x 1 dose
Mecamylamine
mecamylamine 1.25-5 mg PO x 1 dose
Isosorbide Dinitrate
Isosorbide dinitrate 5-20 mg PO x 1 dose
Melatonin
melatonin 3 mg PO x 1 dose
Midodrine
midodrine 2.5-10 mg PO x 1 dose
Modafinil
modafinil 100-200 mg PO x 1 dose
Octreotide
octreotide 12.5-50 mcg Subcutaneous x 1 dose
Placebo
lactose tablet x 1 pill
Propranolol
Propranolol 10-80 mg PO x 1-2 dose
Modafinil & Propranolol
Modafinil 100-200 mg PO x 1 dose AND Propranolol 20 mg PO x 1 dose
Sertraline
sertraline 25-50 mg PO x 1 dose
IV Saline
1 liter IV over 2 hours
Drinking Water
16 fluid ounces
Breathing Device
Breathing through a dead space tube
memantine
memantine 5-20 mg PO x 1 dose
Abdominal binder
Using large blood pressure cuffs linked together, they are wrapped around the subjects abdomen and inflated to generate increased pressure to below tolerably threshold.
Vanderbilt University Autonomic Dysfunction Center, Nashville
National Center for Advancing Translational Sciences (NCATS)
NIH
Satish R. Raj
OTHER